IBA343 is an antibody-drug conjugate (ADC) that Takeda placed its major bets on last year, and the company said it had a phase 3 success for the drug.
Arcotatug tavatecan, or IBI343, or TAK-921, is a molecule that provides a cytotoxic exatecan payload when it binds to cells that express the CLDN18.2 protein. In 2024, Astellas received approval for its anti-CLDN18.2 antibody. Other drug developers are searching for opportunities to target the same “transmembrane protein”, Claudin-18.2, with new modalities to achieve better results.
The phase 3 victory puts Innovent at the lead in the race to bring CLDN18.2 next-generation drugs to market. Innovent achieved the win in a phase 3 clinical trial of 464 patients with locally advanced unresectable or metastatic CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma (GEJ) in China and Japan. Patients had already been treated with at least two systemic therapies.
The progression-free survival (PFS) was significantly improved with IBI343 compared with investigator-selected control arms, including chemotherapy agents, at the first interim analysis. One of the key endpoints of the study was PFS.
Innovent’s statement is missing the numbers for the PFS win or adverse events. The effectiveness was described as “excellent,” and the safety and tolerability were described as “good” by physicians quoted in the press release, and there is little gastrointestinal toxicity. Innovent is keeping the data back for academic conferences or journals. The biotech has yet to comment on the other primary endpoint, overall survival.
China’s National Medical Products Administration has given IBI343 a Priority Review. It is the first time a CLDN18.2-directed ADC has started regulatory review, Innovent said. When Innovent teamed up with Takeda last year, it also kept rights to the drug candidate in Greater China.
Takeda paid $1.2 billion for the rights to IBI343, as well as a bispecific candidate dubbed IBI363. Studies of IBI343 in first-line gastric and pancreatic cancer are underway.
Several companies are vying for similar opportunities. In 2022, AstraZeneca received a license for a CLDN18.2 bispecific, and in 2023, it formed an agreement with an ADC. Last year, Astellas acquired an ADC when competitors were all around its fledgling CLDN18.2 franchise. Moderna joined the fray in 2023. In 2024, Merck & Co. returned their CLDN18.2 candidate from its collaboration with Kelun-Biotech.
The global oncology sector received a significant boost as Innovent announced a positive Phase 3 clinical trial outcome for its Takeda-partnered ADC program. The development follows a major $1.2 billion collaboration agreement and represents an important milestone for both companies as they seek to expand their presence in the rapidly growing cancer treatment market.
The successful trial outcome highlights the increasing importance of ADC technologies in modern oncology, where targeted therapies are becoming a cornerstone of cancer treatment strategies.
ADC Program Achieves Key Clinical Milestone
The positive Phase 3 results mark a major achievement for the partnered ADC candidate. Late-stage clinical studies are designed to confirm both efficacy and safety in larger patient populations, making success at this stage a critical step toward potential regulatory submissions.
For Innovent and Takeda, the latest ADC data provide additional validation of their development strategy and strengthen confidence in the program’s commercial potential.
An ADC, or antibody-drug conjugate, combines the targeting precision of monoclonal antibodies with the cancer-killing power of highly potent therapeutic agents. This approach allows an ADC to deliver treatment directly to cancer cells while reducing exposure to healthy tissues.
As a result, ADC therapies have become one of the most promising areas of oncology innovation, attracting substantial investment from pharmaceutical and biotechnology companies worldwide.
Strategic Importance of the $1.2 Billion ADC Agreement
The substantial collaboration agreement reflects growing industry confidence in ADC technology and its future role in cancer care. Strategic partnerships enable companies to combine scientific expertise, development resources, and commercial capabilities to accelerate innovation.
For Innovent, the deal provided additional support for advancing its ADC pipeline, while Takeda gained access to a potentially valuable oncology asset with global market potential.
The latest clinical victory enhances the competitive standing of the partnered ADC program within a crowded oncology landscape. As multiple companies race to develop next-generation targeted therapies, positive Phase 3 data can significantly improve market positioning and attract greater attention from healthcare providers and investors.
Strong clinical evidence may also support future expansion opportunities for the ADC across additional patient populations and indications.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
